Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 11/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL541948 | 0.80 | ESR1 (0.55) | ESR1ESR2EPHX2AOC3CA12 | |
| SCHEMBL730985 | 0.78 | ESR1 (0.40) | ESR1ESR2EPHX2CA12CA1 | |
| SCHEMBL733028 | 0.78 | ESR1 (0.40) | ESR1ESR2EPHX2LMNA | |
| SCHEMBL28430363 | 0.78 | ESR1 (0.56) | ESR1ESR2EPHX2AOC3CA12 | |
| Methylamine SCHEMBL27463475 | 0.75 | ESR1 (0.50) | ESR1ESR2EPHX2AOC3CA12 | |
| Methylamine SCHEMBL27489583 | 0.74 | ESR1 (0.49) | ESR1ESR2EPHX2AOC3CA12 | |
| Methylamine SCHEMBL28743725 | 0.74 | ESR1 (0.49) | ESR1ESR2EPHX2AOC3CA12 | |
| Methylamine SCHEMBL27501710 | 0.72 | ESR1 (0.47) | ESR1ESR2EPHX2AOC3CA12 | |
| SCHEMBL24566859 | 0.72 | ESR1 (0.50) | ESR1ESR2EPHX2AOC3CA12 | |
| SCHEMBL2549767 | 0.71 | ESR1 (0.46) | ESR1ESR2EPHX2AOC3CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024146922-A1 | C5AR1 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | DOMPE' FARMACEUTICI SPA (IT) | 2024-07-11 | — | — | WO | claimed |
| EP-4397306-A1 | C5AR1 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | Dompe' Farmaceutici S.P.A. (IT) | 2024-07-10 | — | — | EP | claimed |
| US-20240180888-A1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | DOMPE' FARMACEUTICI SPA (IT) | 2024-06-06 | — | — | US | claimed |
| EP-4308114-A1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | Dompe' Farmaceutici SpA (IT) | 2024-01-24 | — | — | EP | claimed |
| CN-117337176-A | C5AR1 inhibitors for treating hypersensitivity to taxanes | 东佩制药股份公司 | 2024-01-02 | — | — | CN | claimed |
| US-20200397725-A1 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | DOMPE' FARMACEUTICI S.P.A. (IT) | 2020-12-24 | — | — | US | claimed |
| EP-3723744-A2 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | Dompé farmaceutici S.p.A. (IT) | 2020-10-21 | — | — | EP | claimed |
| WO-2019115493-A2 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | DOMPE' FARMACEUTICI S.P.A. (IT) | 2019-06-20 | — | — | WO | claimed |
| EP-3498269-A1 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | Dompé farmaceutici S.p.A. (IT) | 2019-06-19 | — | — | EP | claimed |
| US-8026367-B2 | (R)-arylalkylamino derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2011-09-27 | — | — | US | claimed |
| US-20090124664-A1 | (R)-Arylalkylamino Derivatives and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-05-14 | — | — | US | claimed |
| EP-1951663-A2 | (R)-ARYLKYLAMINO DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' pha.r.ma s.p.a. (IT) | 2008-08-06 | — | — | EP | claimed |
| WO-2007060215-A2 | (R)-ARYLKYLAMINO DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA S.P.A. (IT) | 2007-05-31 | — | — | WO | claimed |
| WO-2024146922-A1 | C5AR1 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | DOMPE' FARMACEUTICI SPA (IT) | 2024-07-11 | — | — | WO | disclosed |
| EP-4397306-A1 | C5AR1 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | Dompe' Farmaceutici S.P.A. (IT) | 2024-07-10 | — | — | EP | disclosed |
| US-20240180888-A1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | DOMPE' FARMACEUTICI SPA (IT) | 2024-06-06 | — | — | US | disclosed |
| US-8026367-B2 | (R)-arylalkylamino derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2011-09-27 | — | — | US | disclosed |
| US-20090124664-A1 | (R)-Arylalkylamino Derivatives and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-05-14 | — | — | US | disclosed |
| EP-1951663-A2 | (R)-ARYLKYLAMINO DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' pha.r.ma s.p.a. (IT) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007060215-A2 | (R)-ARYLKYLAMINO DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA S.P.A. (IT) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180888-A1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | C5AR1, C5AR2, C3AR1 | ESR1 902/4885ESR2 2989/4885EPHX2 1122/4885 |
| US-20090124664-A1 | (R)-Arylalkylamino Derivatives and Pharmaceutical Compositions Containing Them | C3AR1, C5AR1, CCR8 | ESR1 3360/4885ESR2 2787/4885EPHX2 1208/4885 |
| US-20200397725-A1 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | C5AR2, C5AR1, C3AR1 | ESR1 2742/4885ESR2 3350/4885EPHX2 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.